Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent
nephropathy.
Authors
Attie AD, Schueler KM, Keller MP, Mitok KA, Simonett SP, Hudkins KL, Mehrotra K,
Graham MJ, Lee RG, Alpers CE
Submitted By
Alan Attie on 5/5/2021
Status
Published
Journal
Laboratory investigation; a journal of technical methods and pathology
Year
2021
Date Published
Volume : Pages
Not Specified
:
Not Specified
PubMed Reference
33911188
Abstract
The etiology of diabetic nephropathy in type 2 diabetes is multifactorial.
Sustained hyperglycemia is a major contributor, but additional contributions
come from the hypertension, obesity, and hyperlipidemia that are also commonly
present in patients with type 2 diabetes and nephropathy. The leptin deficient
BTBR ob/ob mouse is a model of type 2 diabetic nephropathy in which
hyperglycemia, obesity, and hyperlipidemia, but not hypertension, are present.
We have shown that reversal of the constellation of these metabolic
abnormalities with leptin replacement can reverse the morphologic and functional
manifestations of diabetic nephropathy. Here we tested the hypothesis that
reversal specifically of the hypertriglyceridemia, using an antisense
oligonucleotide directed against ApoC-III, an apolipoprotein that regulates the
interactions of VLDL (very low density lipoproteins) with the LDL receptor, is
sufficient to ameliorate the nephropathy of Type 2 diabetes. Antisense treatment
resulted in reduction of circulating ApoC-III protein levels and resulted in
substantial lowering of triglycerides to near-normal levels in diabetic mice
versus controls. Antisense treatment did not ameliorate proteinuria or
pathologic manifestations of diabetic nephropathy, including podocyte loss.
These studies indicate that pathologic manifestations of diabetic nephropathy
are unlikely to be reduced by lipid-lowering therapeutics alone, but does not
preclude a role for such interventions to be used in conjunction with other
therapeutics commonly employed in the treatment of diabetes and its
complications.
Investigators with authorship
Name
Institution
Charles Alpers
University of Washington
Alan Attie
University of Wisconsin-Madison
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!